Penumbra Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Penumbra ha aumentado sus beneficios a una tasa media anual de 5.9%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.5% anual. Los ingresos han ido creciendo a una tasa media de 16.8% al año. La rentabilidad financiera de Penumbra es de 7.7%, y sus márgenes netos son de 8.6%.

Información clave

18.2%

Tasa de crecimiento de los beneficios

15.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	17.1%
Rentabilidad financiera	7.8%
Margen neto	8.5%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors

Jun 22

Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult

Jun 02

We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn

Apr 01

Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Feb 23

Penumbra Riding Higher On Upcoming Launches And Rerating

Jan 12

Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy

Nov 03

Penumbra cut to Neutral at Citi on macro concerns

Oct 05

Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan

Sep 22

Penumbra stock rises ~11% after announcing European launch of catheters for stroke care

Sep 07

Sector Rerating Has Cast A Shadow Over Penumbra

Aug 18

Penumbra gains as RBC initiates at Outperform with 59% upside

Jul 18

Penumbra: Multiple Downside Targets, Rescued By Long-Term Value Proposition

Jun 10

Penumbra A Little Beaten Down Despite Strong Growth Opportunities

Mar 01

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Penumbra. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:PEN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	1,096	93	528	89
31 Dec 23	1,059	91	506	84
30 Sep 23	995	41	492	80
30 Jun 23	938	29	475	81
31 Mar 23	885	6	462	79
31 Dec 22	847	-2	450	79
30 Sep 22	830	-31	439	81
30 Jun 22	806	-19	425	76
31 Mar 22	782	-6	401	74
31 Dec 21	748	5	378	105
30 Sep 21	710	34	376	81
30 Jun 21	671	16	358	90
31 Mar 21	592	-5	327	93
31 Dec 20	560	-16	287	88
30 Sep 20	539	-10	285	72
30 Jun 20	527	11	278	60
31 Mar 20	556	39	286	53
31 Dec 19	547	48	273	52
30 Sep 19	523	45	259	50
30 Jun 19	495	15	245	45
31 Mar 19	471	12	232	40
31 Dec 18	445	7	226	36
30 Sep 18	420	9	216	34
30 Jun 18	392	28	207	33
31 Mar 18	363	13	196	33
31 Dec 17	334	5	184	32
30 Sep 17	311	-7	174	29
30 Jun 17	294	5	166	28
31 Mar 17	279	9	158	26
31 Dec 16	263	15	148	24
30 Sep 16	245	18	136	23
30 Jun 16	228	6	125	21
31 Mar 16	205	3	115	20
31 Dec 15	186	1	102	18
30 Sep 15	167	0	92	17
30 Jun 15	149	-1	82	16
31 Mar 15	138	-1	72	15
31 Dec 14	126	-1	64	16
31 Dec 13	89	1	45	14

Ingresos de calidad: PEN tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (8.5%) de PEN son superiores a los del año pasado (0.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de PEN han crecido un 5.9% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de PEN en el último año (1341%) supera su media de 5 años (18.2% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de PEN en el último año (1341%) superó al de la industria Medical Equipment 2.9%.

Penumbra Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Penumbra, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Penumbra, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Penumbra, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Penumbra, Inc. Reiterates Earnings Guidance for the Year 2024

Penumbra, Inc., Annual General Meeting, Jun 05, 2024

Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots

Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors

Penumbra, Inc. to Report Q1, 2024 Results on May 07, 2024

Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Executive VP notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024

Now 21% overvalued after recent price rise

Now 23% overvalued after recent price rise

Penumbra, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Some Investors May Be Worried About Penumbra's (NYSE:PEN) Returns On Capital

Executive VP notifies of intention to sell stock

Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism

A Look At The Fair Value Of Penumbra, Inc. (NYSE:PEN)

Now 21% undervalued after recent price drop

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Penumbra, Inc. Announces Latest STRIKE-PE Data Evaluating Penumbra's Indigo Aspiration System with Lightning

Price target decreased by 8.5% to US$301

Penumbra: Appeal Improves, Just Not Appealing Yet

Co-Founder exercised options and sold US$2.0m worth of stock

Now 20% undervalued after recent price drop

Penumbra, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Returns On Capital Signal Tricky Times Ahead For Penumbra (NYSE:PEN)

Co-Founder exercised options and sold US$2.8m worth of stock

Executive VP notifies of intention to sell stock

Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy

A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Co-Founder notifies of intention to sell stock

Consensus EPS estimates increase by 16%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Founder exercised options and sold US$3.0m worth of stock

Penumbra, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger

Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors

Co-Founder exercised options and sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult

Penumbra, Inc. Updates Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$154k worth of stock

We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Price target increased by 11% to US$291

Price target increased by 7.2% to US$272

Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Presiding Independent Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Penumbra, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Penumbra Riding Higher On Upcoming Launches And Rerating

Penumbra, Inc. Launches Latest Innovation in Mechanical Thrombectomy, Lightning Flash

Price target increased to US$228

Executive VP notifies of intention to sell stock

Executive VP exercised options and sold US$259k worth of stock

Penumbra, Inc. Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding Real System Platform

Insufficient new directors

Third quarter 2022 earnings released: US$0.06 loss per share (vs US$0.24 profit in 3Q 2021)

Penumbra, Inc. Provides Revenue Guidance for the Year 2023

Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy

Executive VP exercised options and sold US$256k worth of stock

Penumbra, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Penumbra cut to Neutral at Citi on macro concerns

Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan

Desglose de ingresos y gastos
Beta